This is an unfortunately good point: will patient noncompliance on Molnupiravir treatment regimes bring on the viral-mutant problems that many have worried about? I haven't been as concerned about that, but this would be the way it could happen. . .https://twitter.com/zeynep/status/1467890223145172996 …
-
-
We have dealt with this issue before with TB. Standard therapy involves taking multiple antibiotics for 6 months. Gaps are a main driver of resistance. For this reason, directly observed therapy (DOT) is used to monitor compliance, supplemented w/PH law. https://www.health.ny.gov/publications/3705.pdf …
-
Yes, very aware of the comparison. A few key differences, no? The benefit to patient is unequivocal, and evolution occurs under a background rate of mutation—it's not like the antibiotics are mutagenic. But yes, obviously, even then, it is a problem.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.